China's top market regulator summons Alibaba, Meituan, JD.com over delivery price war
Alibaba Group Holding 's Ele.me,
Meituan , and
JD.com – urging them to engage in 'rational' competition amid a prolonged price war.
The meeting aimed to 'further regulate promotion behaviours, encourage rational competition, and foster a healthy ecosystem and win-win situation for consumers, merchants, delivery riders, and platform operators', the regulator said in an announcement.
Alibaba owns the South China Morning Post.
The SAMR said those companies must adhere to e-commerce, anti-unfair competition, and food safety laws, and must take on their responsibilities.
In a separate meeting on the same day, the regulator addressed food safety concerns related to live-streaming e-commerce. It said that some food items sold during recent live-streamed sessions contained excessive food additives or pesticide residues.
Representatives from various live-streaming platforms and influencer agencies attended that meeting, although the SAMR did not disclose any names.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South China Morning Post
34 minutes ago
- South China Morning Post
4 more Hong Kong premium taxi fleets hit the streets after getting full licences
Four more premium taxi service fleets hit the streets on Monday after securing full licences from authorities. Advertisement A Transport Department spokesman said it had granted full taxi fleet licences to four firms, allowing them to operate for five years. 'The four fleets officially commenced services [on Monday],' he said. The four fleets are run by Big Boss Taxi Company, CMG Fleet Management, Sino Development (International) and Tai Wo Management. Sino Development's Big Bee fleet is offering a mixed taxi service, while the other three will only operate urban cabs. Advertisement Earlier this month, SynCab received the same licence to offer premium taxi services in the city.
South China Morning Post
an hour ago
- South China Morning Post
GSK signs US$12.5 billion licence deal with Hengrui as China rises in global pharmaceuticals
GlaxoSmithKline (GSK) will pay a Chinese company US$12.5 billion for exclusive global rights to develop a dozen drugs, in a landmark deal that underscores how China's research labs are snapping up market share in the global pharmaceutical and biomedical industries. The deal would give GSK the rights to develop a drug for treating chronic obstructive pulmonary disease (COPD) called HRS-9821, as well as 11 of the preclinical programmes owned by Jiangsu Hengrui Pharmaceuticals. The global rights exclude mainland China, Taiwan, Hong Kong and Macau, according to a statement to the Hong Kong stock exchange on Monday. The deal is the latest in a string of transactions between multinational firms and Chinese drug developers, which have bolstered China's share of global licensing deal value to 28 per cent in 2024 from 1 per cent in 2019. Pfizer agreed in May to pay US$1.25 billion to Shenyang-based 3SBio for the exclusive right to develop the Chinese company's drug for treating solid tumours. China's pharmaceutical out-licensing value soared to almost US$66 billion in the first six months of 2025, more than the whole of last year, according to a July 14 report from China Post Securities. For multinational companies, the deals gave them exclusive products to expand their portfolio and pipelines, while the Chinese developers saw them as opportunities to cash in on prior work and fund new projects. The GSK corporate flag next to a Chinese national flag outside its office building in Shanghai on July 12, 2013. Photo: Reuters Hengrui, established in the Jiangsu provincial city of Lianyungang in 1997, would receive a US$500 million upfront payment and charge US$12 billion to GSK upon the achievement of development, regulatory approval and sales milestones. 'The signing of the agreement will help expand the international market for HRS-9821 and multiple innovative medicines in various therapeutic areas, including oncology, respiratory, immunology and inflammation, providing high-quality treatment options for patients worldwide,' Hengrui said in a statement.
South China Morning Post
2 hours ago
- South China Morning Post
Why some Chinese students are skipping elite universities amid job market fears
After underperforming in China's national college entrance exam in June, Lu Jie was accepted into a computer science and technology programme earlier this month at a lesser-known polytechnic university in central China's Hunan province. 'Good schools had too many applicants for this major, so I had to choose a lower-ranked one to pursue it,' Lu said. The results for the exam, better known as the gaokao , have been released over the past two weeks – marking a life-changing moment for students like Lu. Now more than ever, students are opting for majors with strong job prospects over prestigious universities. A focus on immediate employability and job security is eclipsing long-term aspirations and personal interests. Driving this trend is a growing oversupply of college graduates , intensifying competition in the job market amid a challenging economic climate. Computer science has long been a highly popular major, Lu said, but the rise of artificial intelligence (AI) – widely expected to create new job opportunities – has fuelled even greater demand over the past couple of years.
